<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897895</url>
  </required_header>
  <id_info>
    <org_study_id>2014-16</org_study_id>
    <nct_id>NCT02897895</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Value of the Follow-up of CALCIneurin Activity to MOdulate Calcineurin Inhibitors-induced Immunosuppression in Lung Transplantation</brief_title>
  <acronym>CalciMo-TP</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an interventional, multicentre, prospective, randomized, controlled,
      single-blind, comparative trial of two processes for adjusting the inhibitor of calcineurin
      (CNI) dosage in lung transplant recipients. Recipients will be stratified by transplant
      center and according to the underlying lung disease (affected with cystic fibrosis or not)
      and will be randomized to either evaluation of calcineurin activity (CN-a) in combination
      with CNI blood levels versus CNI blood levels alone in a 1:1 ratio. The objective is to
      compare the proportion of acute rejection that has required a specific curative treatment at
      6 months after transplantation between patients in the two groups.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of episodes of acute rejection after LTx</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>new strategy of immunosuppression monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>evaluation of calcineurin activity (CN-a) in combination with CNI blood levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>strategy of reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CNI (inhibitor of Calcineurin) blood levels alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>levels of CNI in whole blood</intervention_name>
    <arm_group_label>new strategy of immunosuppression monitoring</arm_group_label>
    <arm_group_label>strategy of reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)</intervention_name>
    <arm_group_label>new strategy of immunosuppression monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient placed on the national waiting list for lung transplantation

          -  First de novo lung transplantation (single or double LTx)

          -  Prevention of allograft rejection by a usual immunosuppressive regimen including CNI
             (cyclosporine or tacrolimus)

        Exclusion Criteria:

          -  Previous lung transplantation or other solid organ transplantation

          -  Combined lung transplantation with either liver or renal transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urielle Desalbres</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique HÃ´pitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martine Reynaud Gaubert, Professor</last_name>
    <email>martine.reynaud@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>reynaud gaubert martine</last_name>
      <email>martine.reynaud@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>reynaud gaubert martine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung transplantation in end-stage lung diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

